CL2017002332A1 - Derivados de benzimidazol como inhibidores de bromodominio - Google Patents
Derivados de benzimidazol como inhibidores de bromodominioInfo
- Publication number
- CL2017002332A1 CL2017002332A1 CL2017002332A CL2017002332A CL2017002332A1 CL 2017002332 A1 CL2017002332 A1 CL 2017002332A1 CL 2017002332 A CL2017002332 A CL 2017002332A CL 2017002332 A CL2017002332 A CL 2017002332A CL 2017002332 A1 CL2017002332 A1 CL 2017002332A1
- Authority
- CL
- Chile
- Prior art keywords
- benzimidazole derivatives
- bromodomain inhibitors
- salts
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
<p>Compuestos de fórmula (I) y sales de los mismos: en la que R1, R2, R3, R4 son como se han definido en la presente memoria. Se ha encontrado que los Compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas de bromodominio a, por ejemplo, residuos de lisina acetilados y por lo tanto pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y cánceres.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504689.9A GB201504689D0 (en) | 2015-03-19 | 2015-03-19 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002332A1 true CL2017002332A1 (es) | 2018-03-16 |
Family
ID=53052091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002332A CL2017002332A1 (es) | 2015-03-19 | 2017-09-14 | Derivados de benzimidazol como inhibidores de bromodominio |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10442786B2 (es) |
| EP (2) | EP3271349B1 (es) |
| JP (1) | JP6419990B2 (es) |
| KR (1) | KR102072850B1 (es) |
| CN (1) | CN107635989B (es) |
| AR (1) | AR103934A1 (es) |
| AU (1) | AU2016232217B2 (es) |
| BR (1) | BR112017019779B1 (es) |
| CA (1) | CA2979504C (es) |
| CL (1) | CL2017002332A1 (es) |
| CO (1) | CO2017009992A2 (es) |
| CR (1) | CR20170430A (es) |
| CY (1) | CY1121855T1 (es) |
| DK (1) | DK3271349T3 (es) |
| DO (1) | DOP2017000213A (es) |
| EA (1) | EA033594B1 (es) |
| ES (1) | ES2735417T3 (es) |
| GB (1) | GB201504689D0 (es) |
| HR (1) | HRP20191186T1 (es) |
| HU (1) | HUE044414T2 (es) |
| IL (1) | IL254318B (es) |
| LT (1) | LT3271349T (es) |
| MA (2) | MA41778A (es) |
| ME (1) | ME03485B (es) |
| MX (1) | MX2017012023A (es) |
| PE (1) | PE20180032A1 (es) |
| PH (1) | PH12017501620A1 (es) |
| PL (1) | PL3271349T3 (es) |
| PT (1) | PT3271349T (es) |
| RS (1) | RS59056B1 (es) |
| SG (1) | SG11201707356QA (es) |
| SI (1) | SI3271349T1 (es) |
| TW (1) | TW201706257A (es) |
| UY (1) | UY36589A (es) |
| WO (1) | WO2016146738A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US10501438B2 (en) | 2015-08-11 | 2019-12-10 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| EP3334719B1 (en) | 2015-08-12 | 2021-09-15 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| JP2020516672A (ja) | 2017-04-18 | 2020-06-11 | セルジーン クオンティセル リサーチ，インク． | 治療用化合物 |
| CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
| US20210261539A1 (en) * | 2018-02-06 | 2021-08-26 | Shanghai Haihe Pharmaceutical Co., Ltd. | Compound having bet inhibitory activity and preparation method and use therefor |
| CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| CA3132628A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| JP2022534472A (ja) * | 2019-04-24 | 2022-08-01 | コンバージーン・リミテッド・ライアビリティ・カンパニー | 小分子ブロモドメイン阻害剤およびそれらの使用 |
| US20220227709A1 (en) * | 2019-04-29 | 2022-07-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating schistosoma infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| NZ571691A (en) | 2006-03-31 | 2011-07-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor |
| EP2493310A4 (en) * | 2009-10-27 | 2014-03-12 | Glaxosmithkline Llc | BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| LT2970265T (lt) | 2013-03-15 | 2018-09-25 | Plexxikon Inc. | Heterocikliniai junginiai ir jų panaudojimas |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015004534A2 (en) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
-
2015
- 2015-03-19 GB GBGB1504689.9A patent/GB201504689D0/en not_active Ceased
-
2016
- 2016-03-15 AR ARP160100683A patent/AR103934A1/es unknown
- 2016-03-17 MX MX2017012023A patent/MX2017012023A/es unknown
- 2016-03-17 ES ES16710214T patent/ES2735417T3/es active Active
- 2016-03-17 MA MA041778A patent/MA41778A/fr unknown
- 2016-03-17 EP EP16710214.4A patent/EP3271349B1/en active Active
- 2016-03-17 SG SG11201707356QA patent/SG11201707356QA/en unknown
- 2016-03-17 EP EP19174047.1A patent/EP3549939A1/en not_active Withdrawn
- 2016-03-17 PE PE2017001543A patent/PE20180032A1/es unknown
- 2016-03-17 BR BR112017019779-0A patent/BR112017019779B1/pt active IP Right Grant
- 2016-03-17 CN CN201680027314.8A patent/CN107635989B/zh active Active
- 2016-03-17 RS RS20190986A patent/RS59056B1/sr unknown
- 2016-03-17 KR KR1020177030073A patent/KR102072850B1/ko active IP Right Grant
- 2016-03-17 PT PT16710214T patent/PT3271349T/pt unknown
- 2016-03-17 JP JP2017548404A patent/JP6419990B2/ja active Active
- 2016-03-17 TW TW105108340A patent/TW201706257A/zh unknown
- 2016-03-17 SI SI201630321T patent/SI3271349T1/sl unknown
- 2016-03-17 AU AU2016232217A patent/AU2016232217B2/en not_active Ceased
- 2016-03-17 UY UY0001036589A patent/UY36589A/es not_active Application Discontinuation
- 2016-03-17 HU HUE16710214 patent/HUE044414T2/hu unknown
- 2016-03-17 MA MA046981A patent/MA46981A/fr unknown
- 2016-03-17 ME MEP-2019-171A patent/ME03485B/me unknown
- 2016-03-17 WO PCT/EP2016/055792 patent/WO2016146738A1/en active Application Filing
- 2016-03-17 US US15/559,556 patent/US10442786B2/en active Active
- 2016-03-17 CR CR20170430A patent/CR20170430A/es unknown
- 2016-03-17 DK DK16710214.4T patent/DK3271349T3/da active
- 2016-03-17 LT LTEP16710214.4T patent/LT3271349T/lt unknown
- 2016-03-17 CA CA2979504A patent/CA2979504C/en active Active
- 2016-03-17 EA EA201791973A patent/EA033594B1/ru not_active IP Right Cessation
- 2016-03-17 PL PL16710214T patent/PL3271349T3/pl unknown
-
2017
- 2017-09-04 IL IL254318A patent/IL254318B/en active IP Right Grant
- 2017-09-07 PH PH12017501620A patent/PH12017501620A1/en unknown
- 2017-09-14 CL CL2017002332A patent/CL2017002332A1/es unknown
- 2017-09-19 DO DO2017000213A patent/DOP2017000213A/es unknown
- 2017-09-29 CO CONC2017/0009992A patent/CO2017009992A2/es unknown
-
2019
- 2019-07-01 HR HRP20191186TT patent/HRP20191186T1/hr unknown
- 2019-07-26 CY CY20191100796T patent/CY1121855T1/el unknown
- 2019-08-22 US US16/547,909 patent/US11053212B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002332A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| CO2019001871A2 (es) | Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres. | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CR20160229A (es) | Inhibidires de bromodominio | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| EA201500926A1 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
| BR112016012781A2 (pt) | Novos métodos | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| SV2016005316A (es) | Compuestos y composiciones para inducir condrogénesis | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| BR112016001645A8 (pt) | derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit | |
| UY34615A (es) | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas |